Sinopharm's Wuhan affiliate boosts COVID-19 shot annual capacity to 1 billion doses. CNA [online]. [cit. 2021-11-05]. Dostupné v archivu pořízeném z originálu dne 2021-11-19. (anglicky)
clinicaltrials.gov
CHINA NATIONAL BIOTEC GROUP COMPANY LIMITED. Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above. [s.l.]: [s.n.] Dostupné online. Submitted: August 3, 2020.
UNIVERSIDAD PERUANA CAYETANO HEREDIA. Ensayo Clínico de Fase III, Aleatorio, Doble Ciego y Controlado Con Placebo Paralelo, Para Evaluar la Seguridad y la Eficacia Protectora de la Vacuna Inactivada Contra el SARS-CoV-2 en la Población Sana de 18 años o más, en Perú. [s.l.]: [s.n.] Dostupné online. Submitted: August 18, 2020.
doi.org
dx.doi.org
AL KAABI, Nawal; ZHANG, Yuntao; XIA, Shengli. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021-07-06, roč. 326, čís. 1, s. 35–45. Dostupné online [cit. 2021-11-05]. ISSN0098-7484. DOI10.1001/jama.2021.8565.
XIA, Shengli; ZHANG, Yuntao; WANG, Yanxia. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet. Infectious Diseases. 2021-1, roč. 21, čís. 1, s. 39–51. PMID: 33069281
PMCID: PMC7561304. Dostupné online [cit. 2021-11-05]. ISSN1473-3099. DOI10.1016/S1473-3099(20)30831-8. PMID33069281.
XIA, Shengli; DUAN, Kai; ZHANG, Yuntao. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. JAMA. 2020-09-08, roč. 324, čís. 10, s. 1–10. PMID: 32789505
PMCID: PMC7426884. Dostupné online [cit. 2021-11-05]. ISSN0098-7484. DOI10.1001/jama.2020.15543. PMID32789505.
doi.org
AL KAABI, Nawal; ZHANG, Yuntao; XIA, Shengli. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021-07-06, roč. 326, čís. 1, s. 35–45. Dostupné online [cit. 2021-11-05]. ISSN0098-7484. DOI10.1001/jama.2021.8565.
mb.com.ph
FDA grants EUA to COVID-19 vaccine Sinopharm manufactured by Wuhan affiliate. Manila Bulletin [online]. [cit. 2021-11-05]. Dostupné online. (anglicky)
nih.gov
ncbi.nlm.nih.gov
XIA, Shengli; ZHANG, Yuntao; WANG, Yanxia. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet. Infectious Diseases. 2021-1, roč. 21, čís. 1, s. 39–51. PMID: 33069281
PMCID: PMC7561304. Dostupné online [cit. 2021-11-05]. ISSN1473-3099. DOI10.1016/S1473-3099(20)30831-8. PMID33069281.
XIA, Shengli; DUAN, Kai; ZHANG, Yuntao. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. JAMA. 2020-09-08, roč. 324, čís. 10, s. 1–10. PMID: 32789505
PMCID: PMC7426884. Dostupné online [cit. 2021-11-05]. ISSN0098-7484. DOI10.1001/jama.2020.15543. PMID32789505.